Back to JHPCYView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Non-Small Cell Lung Cancer With HER2- Mutations
View Full LandscapeDrug Information
Target Indication
Non-Small Cell Lung Cancer With HER2- Mutations
Clinical Trial
NCT06430437Last updated: 10/16/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
JSKN003Phase 3
Advanced Solid Tumor
Irinotecan liposome、5-Fluorouracil、LeucovorinPhase 3
Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
X0002 SprayPhase 3
KNEE OSTEOARTHRITIS
RocuroniumPhase 3
Neuromuscular Blockade
HRS-9190Phase 3
Neuromuscular Blockade
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts